• Ampliphi Biosciences Corp., of Richmond, Va., presented data at the Biennial Evergreen International Phage meeting in Olympia, Wash., relating to its use of bacteriophages in the treatment of Pseudomonas aeruginosa, the major cause of lung infections in cystic fibrosis (CF) patients.